The Coronary Sinus Reducer Stent for the Treatment of Refractory Angina Pectoris: From the Conception of Innovation to Clinical Application

Yoav Paz; Liza Grosman-Rimon; Yair Levy; Amihay Shinfeld

doi:10.1097/CRD.0000000000000516

The Coronary Sinus Reducer Stent for the Treatment of Refractory Angina Pectoris: From the Conception of Innovation to Clinical Application

Cardiol Rev. 2022 Dec 28. doi: 10.1097/CRD.0000000000000516. Online ahead of print.

Authors

Yoav Paz¹, Liza Grosman-Rimon², Yair Levy³, Amihay Shinfeld³

Affiliations

¹ From the General Intensive Care Unit, Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
² The Academic College at Wingate, Wingate Institute, Netanya, Israel Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Department of Internal Medicine, Meir Medical Center, Kfar Saba, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

PMID: 36728718
DOI: 10.1097/CRD.0000000000000516

Abstract

The Neovasc Coronary Sinus Reducer Stent (CSRS) was developed for the treatment of patients who continue to suffer from disabling symptoms despite optimal medical therapy. This patient population with refractory angina symptoms is expected to grow, since life expectancy of individuals with atherosclerotic coronary artery disease is increasing. In this paper, we discussed the development of a novel device the CSRS and the upside-down strategy to rebuild a retrograde coronary pressure that was attenuated by the atherosclerotic disease.